Development of next-generation neuromodulatory therapeutics by quadripulse transcranial magnetic stimulation for treatment-resistant depression and elucidation of its therapeutic mechanism - Next-generation neuromodulatory therapeutics by QPS for treatment-resistant depression

Mimura Masaru0 个研究点目标入组 56 人开始时间: 2021年9月16日最近更新: 2023年11月20日

适应症

试验速览

暂无简介。

•Patients with treatment-resistant depression that meet the following conditions:
•- Person who is between 20 and 65 years old at the time of obtaining informed consent.
•- Those who meet the diagnostic criteria for depression in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5).
•- Persons who have a severity of 18 or more on the score of MADRS.
•- Person who is able to obtain written consent.

•- Patients who have cerebral organic diseases (intracranial organic lesions of moderate or higher grade, neurodegenerative diseases, etc.).
•- Patients with a history of seizures or epilepsy, serious or unstable physical illness.
•- Metal implants, pacemakers, people with contraindications for TMS or MRI such as claustrophobia.

发起方

Mimura Masaru